Changing the course of immune-related diseases and ageing.
Immunis is a private biotechnology company researching and developing immune secretome products to address age-driven immune deficits. Immunis has developed a novel method to isolate clinical-grade secreted cellular factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of these beneficial secreted factors and our technology replenishes them. Our investigational IMMUNA product is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations. Immunis' first clinical trial is a Phase 1/2a study of the safety and tolerability of IMMUNA for elderly individuals who have muscle atrophy associated with knee osteoarthritis.